Financial Performance - For the year ended December 31, 2023, total revenue reached HKD 199,683,000, a significant increase of 410% compared to HKD 39,125,000 in 2022[3] - Operating profit from continuing operations was HKD 14,575,000, compared to an operating loss of HKD (10,786,000) in 2022[5] - The net profit attributable to equity holders for the year was HKD 9,842,000, a turnaround from a loss of HKD (31,052,000) in the previous year[6] - Earnings per share for continuing operations improved to HKD 0.63, compared to a loss per share of HKD (0.54) in 2022[6] - The total profit for the year ended December 31, 2023, was HKD 9,842, a recovery from a loss of HKD 31,052 in 2022[23] - The net profit increased to approximately HKD 9,800,000 for the year ended December 31, 2023, compared to a net loss of about HKD 31,100,000 for the year ended December 31, 2022, driven by significant growth in the healthcare business, with sales of healthcare products exceeding three times that of 2022[75] Revenue Breakdown - For the year ended December 31, 2023, the total revenue from external customers was HKD 191,388, an increase from HKD 40,421 in 2022, representing a growth of 373%[21] - The health business segment generated revenue of HKD 191,170 for the year ended December 31, 2023, compared to HKD 39,129 in 2022, indicating a significant increase of 388%[24] - The total revenue for the health business increased approximately fourfold from about HKD 39,100,000 in the year ended December 31, 2022, to about HKD 200,000,000 in the year ended December 31, 2023[64] - The health business revenue for the year ended December 31, 2023, was approximately HKD 191,100,000, representing an increase of about 380% compared to approximately HKD 39,100,000 for the year ended December 31, 2022[65] Cost and Expenses - The cost of sales for the healthcare business was HKD (151,077,000), up from HKD (31,961,000) in the previous year, reflecting a 372% increase[5] - Total operating expenses for continuing operations increased to HKD 28,455 in 2023 from HKD 14,372 in 2022, reflecting a rise of 98%[30] - The cost of goods sold for the year ended December 31, 2023, was approximately HKD 151,077,000, compared to HKD 31,961,000 in 2022[44] - Total expenses (excluding cost of sales) increased by approximately 90% to about HKD 34,000,000 for the year ended December 31, 2023, compared to HKD 18,000,000 for the previous year[69] - Referral expenses and other costs rose from HKD 500,000 for the year ended December 31, 2022, to HKD 3,600,000 for the year ended December 31, 2023, mainly due to increased business activities in the healthcare sector[70] Assets and Liabilities - Total assets decreased to HKD 251,775,000 from HKD 284,310,000, representing a decline of approximately 11.4%[8] - Current assets also decreased to HKD 251,387,000 from HKD 283,465,000, a reduction of about 11.3%[8] - Total equity increased to HKD 239,865,000 from HKD 230,800,000, showing a growth of approximately 3.3%[8] - Current liabilities significantly decreased to HKD 11,910,000 from HKD 53,510,000, a reduction of about 77.8%[9] - Trade receivables decreased to HKD 12,979,000 in 2023 from HKD 17,991,000 in 2022, a reduction of 27.8%[45] - The total amount of other receivables and prepayments decreased to HKD 2,914,000 in 2023 from HKD 6,999,000 in 2022[49] Business Operations - The company has launched a health business segment through an international e-commerce platform, focusing on natural growth rather than mergers[18] - The company successfully expanded its B2C model on a popular short video platform in China, generating approximately HKD 18,000,000 in revenue for the year[60] - The company established a strategic cooperation agreement for OEM/ODM business with Beijing Tongrentang (Hong Kong) Co., Ltd. and Zhongke Molecular Biology (Guangdong) Co., Ltd.[61] - The healthcare business will offer products such as ginseng slices, Arctic cod belly, and bird's nest from Indonesia and Malaysia, targeting local market preferences[90] - The company aims to expand its business through established e-commerce cross-border channels and plans to distribute ODM products in the Hong Kong market via multiple sales channels in 2024[92] - A collaboration with Japanese pharmaceutical companies is planned to distribute related medicines through e-commerce sales channels, following the acquisition of a wholesale license from the Hong Kong Department of Health[92] - The company is negotiating with local well-known chain stores to establish counters for selling its products, expected to be implemented before 2025[92] - An official account will be set up on popular social media platforms in Hong Kong to promote its products, leveraging the success of key opinion leaders (KOLs) in China[92] Corporate Governance and Compliance - The company has adopted new and revised Hong Kong Financial Reporting Standards effective from January 1, 2023, which may impact future financial reporting[12] - The company plans to adopt new Hong Kong Financial Reporting Standards that will come into effect in 2024 and 2025, which may impact future financial reporting[16] - The company has complied with the corporate governance code throughout 2023 and will continue to review its governance practices[97] - The company has maintained a sufficient public float of at least 25% of its total issued share capital as required by listing rules[96] - The company did not recommend any dividend for the year ended December 31, 2023, consistent with 2022[36] - No final dividend is recommended for the year ended December 31, 2023, consistent with the previous year[95] Market and Trading Status - The company has suspended its margin trading business in Hong Kong and terminated its operations in New Zealand and Australia during 2022[17] - The group recorded a net foreign exchange loss of approximately HKD 200,000 for the year ended December 31, 2023, compared to a net gain of HKD 3,500,000 for the previous year[79] - The group did not have any significant investments, acquisitions, or disposals during the year ended December 31, 2023[81] - The company's shares have been suspended from trading since April 25, 2023, until further notice[104]
CLSA PREMIUM(06877) - 2023 - 年度业绩